ARTHUR A. LEVIN - 20 Jan 2023 Form 4 Insider Report for Avidity Biosciences, Inc. (RNA)

Role: Chief Scientific Officer
Signature: /s/ John W. Wallen III, Ph.D., J.D., Attorney-in-Fact
Issuer symbol: RNA
Transactions as of: 20 Jan 2023
Net transactions value: $0
Form type: 4
Filing time: 24 Jan 2023, 20:07:54 UTC
Previous filing: 17 Jan 2023
Next filing: 15 Feb 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RNA	Common Stock	Award	$0	+18,000	+1353%	$0.000000	19,330	20 Jan 2023	Direct	F1
holding	RNA	Common Stock						273,872	20 Jan 2023	By family trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RNA	Stock Option (Right to Buy)	Award	$0	+144,000		$0.000000	144,000	20 Jan 2023	Common Stock	144,000	$22.47	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in four equal installments on the first four anniversaries of January 20, 2023, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.
F2	1/48th of the total number of shares subject to the options shall vest on each monthly anniversary of January 20, 2023 (the "Vesting Commencement Date"), subject to the Reporting Person's continuous service to the Issuer on each such vesting date, so that the options shall be fully vested on the fourth anniversary of the Vesting Commencement Date.